

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-0684	SERIAL NO. 09/551,188
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Axel ULLRICH et al.	
		FILING DATE 04/17/2000	GROUP ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
OPE							
	DEC 28 2001						
PATENT & TRADEMARK OFFICE USA							

RECEIVED
JAN 02 2001
TECH CENTER 1600/2800

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
EPA	A1	0504914	09/23/1992	EPO				
EPA	A2	95/02187	01/19/1995	WIPO				
EPA	A3	90/10234	09/07/1990	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EPA	A4	GUSTERSON, R.D. et al. "Prognostic Importance of c-erbB-2 Expression in Breast Cancer," <i>Journal of Clinical Oncology</i> (1992), Vol. 10, No. 7, pp. 1049-1056, American Society of Clinical Oncology.
EPA	A5	PEREZ, Jose L. et al. "Identification and Chromosomal Mapping of a Receptor Tyrosine Kinase with a Putative Phospholipid Binding Sequence in its Ectodomain," <i>Oncogene</i> (1994), Vol. 9, No. 1, pp. 211 - 219.
EPA	A6	KARN, Thomas et al. "Structure, Expression and Chromosomal Mapping of TKT from Man and Mouse: a New Subclass of Receptor Tyrosine Kinases with a Factor VIII-like Domain," <i>Oncogene</i> (1993), Vol. 8, No. 12, pp. 3433-3440.
EPA	A7	CARTER, Paul et al., "Humanization of an anti-p185 ^{HER2} Antibody for Human Cancer Therapy," <i>Proc. Natl. Acad. Sci.</i> (1992), Vol. 89, No. 10, pp. 4285-4289.
EPA	A8	GAZIT, Aviv et al. "Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <i>J. Med. Chem.</i> (1991), Vol. 34, No. 6, pp. 1896-1907, American Chemical Society.

EXAMINER

Eileen B. O'Hara

DATE CONSIDERED

1/31/02

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Eileen B.O. Flanagan

1/31/02

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.